secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-10-23T23:59:59+00:00
Accession:  0001213900-24-089887
Event type: other_material
Sentiment:  positive
Materiality: 0.25
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed adds Johns Hopkins Alzheimer's expert Dr. Barry Greenberg to Scientific Advisory Board
--------------------------------------------------------------------------------

- Dr. Greenberg is Director of Alzheimer's Disease Translational Center at Johns Hopkins University School of Medicine.
- He has over four decades of Alzheimer's research and held leadership roles at AstraZeneca and Neurochem.
- His expertise will guide InMed's INM-901 drug candidate toward human clinical trials for Alzheimer's disease.
- He serves as Editor-in-Chief of 'Alzheimer's & Dementia: Translational Research and Clinical Interventions'.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024089887/0001213900-24-089887-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024089887/ea0218323-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-089887

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer